JP Morgan Chase
RVNC

JP Morgan Chase’s Revance Therapeutics, Inc. RVNC Stock Holding History

JP Morgan Chase’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,400
Closed -$21.1K – 7971
2023
Q4 		$21.1K Hold
2,400
– – ﹤0.01% 6242
2023
Q3 		$27.5K Buy
+2,400
New +$46.1K ﹤0.01% 5988
2023
Q2 		– Sell
-1,600
Closed -$52K – 7408
2023
Q1 		$52K Buy
+1,600
New +$49.9K ﹤0.01% 5685
2022
Q3 		– Sell
-70,400
Closed -$973K – 6939
2022
Q2 		$973K Sell
70,400
-146,200
-67% -$2.25M ﹤0.01% 4117
2022
Q1 		$4.22M Buy
216,600
+25,000
+13% +$379K ﹤0.01% 3150
2021
Q4 		$3.13M Buy
+191,600
New +$3.19M ﹤0.01% 3457

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's RVNC Position: Q1 2025 in Review

JP Morgan Chase sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,298,822 shares — an estimated $3.95M sold.

JP Morgan Chase first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $166M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • JP Morgan Chase reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1,298,822 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.95M.
  • JP Morgan Chase first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
  • JP Morgan Chase's Revance Therapeutics, Inc. position peaked at $166M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.